secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ultragenyx Pharmaceutical Inc. (RARE)
CIK:        0001515673
Form:       8-K
Filed at:   2024-12-19T23:59:59+00:00
Accession:  0000950170-24-138250
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Ultragenyx submits BLA to FDA for UX111 gene therapy in Sanfilippo syndrome type A
--------------------------------------------------------------------------------

- Submitted BLA to FDA seeking accelerated approval for UX111 (AAV gene therapy) in Sanfilippo syndrome type A (MPS IIIA).
- BLA supported by Transpher A study: rapid, sustained CSF heparan sulfate reduction correlated with improved cognitive development vs. natural history.
- Most common adverse events were liver enzyme elevations; majority mild/moderate (Grade 1/2), all resolved.
- In 2024, FDA agreed CSF heparan sulfate can serve as surrogate endpoint for accelerated approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1515673/000095017024138250/0000950170-24-138250-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1515673/000095017024138250/rare-20241219.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-138250

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer